CSPC Innovation Pharmaceutical (300765) Q2 2026 earnings summary

Executive summary

• Revenue surged 208.72% year-over-year to ¥3.24 billion, driven by biopharma and licensing deals.

• Net profit attributable to shareholders reached ¥1.26 billion, reversing a prior loss.

• Biopharma segment became the main revenue driver, with major out-licensing to AstraZeneca and Corbus.

• R&D investment rose 45.72% year-over-year, supporting a robust pipeline in ADCs, mRNA vaccines, and antibodies.

Financial highlights

• Operating cash flow was ¥2.78 billion, up 1,928.74% year-over-year.

• Gross margin for biopharma reached 97.22%, with overall gross margin at 77.12%.

• Basic and diluted EPS were ¥0.9056, up from a loss per share last year.

• Total assets increased 38.75% to ¥8.71 billion; equity attributable to shareholders rose 47.58%.

• Non-recurring gains totaled ¥35.25 million, mainly from government grants and fair value changes.

Outlook and guidance

• Continued focus on biopharma innovation, with multiple late-stage clinical assets and new launches expected.

• Further expansion of global licensing and commercialization partnerships anticipated.

• Ongoing investment in R&D and production capacity to support pipeline and market growth.